Yellow fever virus: historical and current issues regarding recent epidemics and vaccination in Brazil

References

• Downs WG. The Rockefeller Foundation virus program: 1951–1971 with update to 1981. Annu Rev Med. 1982;33:1–29. doi:10.1146/annurev.me.33.020182.000245.
   PubMed Web of Science ®Google Scholar
• Downs WG. Arboviruses. In: Evans AS editor. Viral infections of humans. 2nd. New York, USA: Plenum Medical Book Company; 1982. p. 95–126.
   Google Scholar
• Finlay C. El mosquito hipoteticamente considerado como agente de transmission de la febre amarilla. An Acad Cienc Medicas Habana. 1881;18:147–69.
   Google Scholar
• Nott JC. Yellow fever contrasted to bilious fever – reasons to believe it a disease sui generis – its mode of propagation – remote cause – probable insect or animalcular origin, etc. New Orleans Med Surg J. 1848;4:563–601.
   Google Scholar
• Warren AJ. Landmarks in the conquest of yellow fever. In: Strode GK, editor. Yellow fever. New York, USA: McGraw Hill; 1951. p. 1–37.
   Google Scholar
• Reed W, Carroll J, Agramonte A. The etiology of yellow fever: a preliminary note. Philadelphia Med J. 1900;6:790–96.
   Google Scholar
• Reed W, Carroll J, Agramonte A. The etiology of yellow fever: an additional note. JAMA. 1901;36:431–40.
   Google Scholar
• Theiler M, Smith HH. The use of yellow fever modified by in vitro cultivation for human immunization. J Exp Med. 1937;65:787–800.
   PubMedGoogle Scholar
• Soper FL, Penna HA, Cardoso E, Serafim J, Jr., Frobisher, J, Jr., Pinheiro J. Yellow fever without Aedes aegypti. Study of a rural epidemic in the Vale do Chanaan, Espirito Santo, Brazil, 1932. Am J Hyg. 1933;18:555–87.
   Google Scholar
• Pinheiro FP, Gomes L Immune response to yellow fever vaccine. A symposium on yellow fever; 1980; Belém, Brazil. Pan American Health Organization.
   Google Scholar
• Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet. 2001;358:121–22. doi:10.1016/S0140-6736(01)05341-7.
   PubMed Web of Science ®Google Scholar
• Martin M, Tsai TF, Cropp B, Chang GJJ, Holmes DA, Tseng J, Shieh W-J, Zaki SR, Al-Sanouri I, Cutrona AF, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet. 2001;358:98–104. doi: 10.1016/S0140-6736(01)05327-2
   Google Scholar
• Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL, Monath TP, Rodigues SG, Laval C, Costa ZG, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;358:91–97. doi: 10.1016/S0140-6736(01)05326-0
   Google Scholar
• Ishak R, Howard CR. The thermal stability of yellow fever vaccines. Mem Inst Oswaldo Cruz. 1990;85:339–45. doi:10.1590/S0074-02761990000300011.
   PubMed Web of Science ®Google Scholar
• Penna HA, Bittencourt A. Persistence of yellow fever in brains of monkeys immunized by cerebral inoculation. Science. 1943;97:448–49. doi:10.1126/science.97.2524.448.
   PubMedGoogle Scholar
• Groot H, Ribeiro RB. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull Wid Hlthi Org. 1962;27:699–707.
   PubMed Web of Science ®Google Scholar
• Monath TCP. Neutralizing antibodies responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans. Am J Epidemiol. 1971;93:122–29. doi:10.1093/oxfordjournals.aje.a121232.
   PubMed Web of Science ®Google Scholar
• Pinheiro FP. Yellow fever. In: Braude AI editor. Medical microbiology and infectious diseases. 1st. Philadelphia, PA: WB Saunders Co; 1980. p. 1155–60.
   Google Scholar
• Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody 30–35 years after immunization with yellow fever vaccine. Bull World Health Organ. 1981;59:895–900.
   PubMed Web of Science ®Google Scholar
• WHO - World Health Organization. Background paper on yellow fever vaccine. SAGE Working Group. Geneva, Switzerland: World Health Organization; 2013. 43 pp. [accessed 2019 May 22]. https://www.who.int/immunization/sage/meetings/2013/april/1_Background_Paper_Yellow_Fever_Vaccines.pdf.
   Google Scholar
• WHO - World Health Organization. Vaccines and vaccination against yellow fever. WHO position paper – 269–84. June 2013a. Wky Epidemiol Rec. 2013;88(27):269–83. [accessed 2019 10 May]. http://www.who.int/immunization/sage/previous/en/index.html.
   PubMedGoogle Scholar
• Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: a review. Int J Mol Sci. 2019;18:20–26.
   Google Scholar
• Seeff LB. Natural history of chronic hepatitis C. Hepatol. 2002;36:35–46.
   PubMed Web of Science ®Google Scholar
• Domingo C, Yactayo S, Agbenu E, Demanou M, Schulz AR, Daskalow K, Niedrig M. Detection of yellow fever 17D genome in urine. J Clin Microbiol. 2011;49:760–62. doi:10.1128/JCM.01775-10.
   PubMed Web of Science ®Google Scholar
• Ahuka-Mundeke S, Casey RM, Harris JB, et al. Immunogenicity of fractional-dose vaccine during a yellow fever outbreak – preliminary report. N Engl J Med. 2018. doi:10.1056/NEJMoa1710430.
   PubMed Web of Science ®Google Scholar
• Martins RM, Maia MLS, Farias RH, Camacho LAB, Freire MS, Galler R, Yamamura AMY, Almeida LFC, Lima SMB, Nogueira RMR, et al. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin Immunol. 2013;9:879–88. doi:10.4161/hv.22982.
   PubMed Web of Science ®Google Scholar
• Vannice K, Wilder-Smith A, Hombach J. Fractional-dose yellow fever vaccination - advancing the evidence base. N Engl J Med. 2018;379:603–05. doi:10.1056/NEJMp1803433.
   PubMed Web of Science ®Google Scholar
• WHO - World Health Organization. Yellow fever vaccine: WHO position on the use of fractional doses – June 2017. Wkly Epidemiol Rec. 2017;92(25):345–50.
   PubMedGoogle Scholar
• WHO - World Health Organization. Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines. Replacement of the annex 2 of WHO technical report series, no. 872 and of the amendment to the annex in WHO technical report series, no. 2012;944. [accessed 2019 May 10]. https://www.who.int/biologicals/areas/vaccines/TRS_978_Annex_5.pdf.
   Google Scholar
• Possas C, Lourenço-de-Oliveira R, Tauil PL, Pinheiro FP, Pissinatti A, Cunha RVD, Freire M, Martins RM, Homma A.Yellow fever outbreak in Brazil: the puzzle of rapid viral spread and challenges for immunization. Mem Inst Oswaldo Cruz. 2018;113:e180278.
   PubMed Web of Science ®Google Scholar